SEC Filing Summary: Regentis Biomaterials Ltd. (Form 6-K)
Business Context and Reporting Period
This Form 6-K filing covers the month of July 2026 for Regentis Biomaterials Ltd., a foreign private issuer headquartered in Herzliya, Israel. The report details the status of the Company's Annual General Meeting of Shareholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural notice regarding a shareholder meeting and contains no financial statements or performance data.
Material Changes
There are no material financial changes reported. The primary event is the adjournment of the Annual General Meeting originally scheduled for July 2, 2026, due to a lack of quorum.
Guidance, Outlook, and Management Commentary
Management has announced that the Annual General Meeting will be reconvened on Tuesday, July 9, 2026, at 3:00 p.m. Israel time. The meeting will be held at the offices of the Company's attorneys, Amit, Pollak, Matalon & Co., located at APM House, 18 Raoul Wallenberg St., Building D, 6th floor, Ramat Hachayal, Tel Aviv, Israel. No financial guidance or risk factors were disclosed in this specific filing.
Key Facts for Investor Verification
- The Annual General Meeting scheduled for July 2, 2026, failed to achieve a quorum.
- The meeting has been rescheduled for July 9, 2026, at the same time and location as the original venue.
- No financial results or operational updates were included in this filing.